Danaher (DHR) PT Raised to $272 at Needham & Company; 'Bioprocessing Strength Demonstrates Power of Cytiva/Pall Combination'
Tweet Send to a Friend
Needham & Company analyst Stephen Unger raised the price target on Danaher (NYSE: DHR) to $272.00 (from $209.00) while maintaining ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
